Traduction de «have been key in driving year-to-date » (Néerlandais → Français) :

Newly launched products, such as enoxaparin, losartan, and tacrolimus, have been key in driving year-to-date growth.
Depuis le début de l’année, les produits lancés nouvellement, comme énoxaparine, losaratan et tacrolimus, ont tiré la croissance vers le haut.

Pain medicines were key contributors in OTC. In Europe, Voltaren has been a key business driver, becoming the largest self-medication brand in the German market with a year-to-date 44% market share in the topical analgesic market.
Les analgésiques ont été les principaux contributeurs d’OTC. En Europe, Voltaren a été un moteur de la croissance en devenant la plus grande marque de l’automédication sur le marché allemand, avec une part du marché des analgésiques topiques atteignant 44%.

If Alcon’s year-end closing price had been the only measure used for the impairment test, the value of this investment would have been USD 6.6 billion, or approximately USD 3.8 billion below the year-end carrying value on the Novartis consolidated balance sheet.
Si le test de dépréciation avait été fait uniquement sur la base du cours de clôture de l’action Alcon en fin d’année, la valeur de cet investissement aurait été d'USD 6,6 milliards, soit environ USD 3,8 milliards de moins que sa valeur au bilan consolidé de Novartis en fin d'année.

More than 30 positive regulatory decisions have been achieved to date in 2009 in the US, European Union and Japan.
Plus de trente décisions réglementaires favorables ont été accordées à ce jour en 2009 aux Etats-Unis, dans l’Union européenne et au Japon.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

The year 2008 was the first phase in the transformation or switch to a new structure. The 3 committees of the FAMHP have been created and the selection procedure for the 3 Directors-General initiated.
The year 2008 was the first phase in the transformation or switch to a new structure. The 3 committees of the FAMHP have been created and the selection procedure for the 3 Directors-General initiated.